Latest News:

We are pleased to welcome Dr. Alexander Baumann in our team. As our new of Head Sales & Business Development he will be responsible for sales, marketing and business development related issues. Please contact him to explore cooperation opportunities.

Upcoming Events:

Meet ProQinase´s members at the Targeting The Kinome Conference,

which will be held on December 4th - 6th 2006 in Basel, CH. Dr. Jan Ehlert from our Drug Development group will present ProQinase's “CELLULAR TEST SYSTEM FOR ASSAYING INHIBITORS OF THE KINASE ACTIVITY OF B-RAF VE600” in the poster session.

Recombinant Protein Kinases

New Protein Kinases
3 new protein kinases have now been thoroughly characterized and are available as active enzymes for our customers and our Screening Services in large quantities:

PYK2 - (download datasheet)
TRK-A - (download datasheet)
PAK3 - (download datasheet)

in vitro Screening Services

Please discover our new MiniProfiler Service

Listening to our customers, ProQinase decided to close the “gap” between our large scale, standard IC50 assay service (many compounds on up to 4 kinases in parallel), and the FreeSelect Service (IC50s of one compound on up to 32 kinases in parallel for EUR 4,000 / USD 4,800). For this service additional kinases an external supplier have been validated increasing the panel of enzymes for selection to 169 protein kinases. The MiniProfiler Service offers the option to test 8 compounds within a day on 24 kinases, and receive IC50s-profiles covering 10 concentrations in semi-log steps for a price of EUR 15,000 / USD 18,000. Please inquire for detailed information.


ProQinase's HTS services are optimized for large scale parallel screening of several kinases with a minimum consumption of compounds. Parallel HTS with 4 kinases is carried out with no more than 5 µl stock solution per compound from a single compound plate. For screens with at least 10.000 compounds in 384 well format we guarantee a price of no more than 1.00 € / 1.20 US-$ per data point, but even much lower prices are possible.

Cellular Assays

ProQinase launches new cellular test systems:
The tyrosine kinase receptor KIT (also SCFR, CD117) is a growth factor receptor expressed by a variety of tumor cells. KIT over-expression indicates a role for KIT in tumor progression, and thus qualifies KIT as an anti-cancer target. Blockade of KIT by Gleevec has been effective in chronic myelogenous leukemia and gastrointestinal tumors. The human neuroepithelioma cell line SK-N-MC is known to over-express KIT. Stimulation of these cells with the KIT ligand, human stem cell factor (SCF), results in a robust receptor autophosphorylation. Based on these cells, ProQinase has developed a test system to assay the efficacy of potential KIT inhibitors in a cellular context.

Cellular Phosphorylation Assays offered by ProQinase

in vivo Tumor Models

ProQinase offers new in vivo tumor models

ERRB2-Receptor: This modell is taking advantage of a genetically engineered mouse NIH3T3 fibroblasts cell line, which over-expresses the HER2/c-erbB2 receptor tyrosine kinase under the control of a tetracycline regulated promoter. Treatment of the cells with doxycycline leads to a repression of the ERBB2 receptor expression (rep), causing significant tumor regression. This is an excellent positive control for animal studies to test the efficacy of ERRB2 Receptor inhibitors. Additional cell lines are in preparation, please inquire for detailed information.

Clinical Biomarker Analysis

ProQinase expands its Clinical Biomarker Analysis service by two additional biomarkers, ANG1 and KIT (sSCFR).In the past five years, ProQinase has built a profound expertise in accompanying clinical trials with regard to the determination of clinical biomarkers. To support our customers in this field, ProQinase covers the following aspects, relevant for the incorporation of protein biomarkers into clinical trials:

• we discuss a qualified biomarker sample scheduling
• we provide you with guidelines ready to be imported into your study protocol
• we give advice in every technical aspect during on-site implementation
• we are ready to provide data at any time during the course of the clinical trial allowing for input of biomarker data e.g. in dosage decisions
• we provide the results in a data base ready format based on customers request
• we finalize the project with a detailed report

Please find below a list of currently available protein markers determined in patients serum/plasma. If your drug target or aim of the study requires additional markers please discuss with us if a realisation is feasible.

 X = preferred source
(X) = on request
 X* = platelet-poor plasma